"10.1371_journal.pone.0054826","plos one","2013-01-31T00:00:00Z","Costanza Bogani; Niccolò Bartalucci; Serena Martinelli; Lorenzo Tozzi; Paola Guglielmelli; Alberto Bosi; Alessandro M Vannucchi; Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative","Department of Medical and Surgical Care, Section of Hematology, University of Florence, Florence, Italy","Conceived and designed the experiments: CB NB PG AMV. Performed the experiments: CB NB SM LT PG. Analyzed the data: CB NB LT PG AB AMV. Wrote the paper: CB NB LT PG AMV.","A.M. Vannucchi, participated in advisory board meeting (Novartis, Italfarmaco). The JAK1/JAK2 kinase ATP-competitive inhibitors AZD1480 [44] and INC424 (ruxolitinib) were provided by D. Huszar (AstraZeneca, Waltham, MA, USA) and T. Radimeski (Novartis, Basel, CH), respectively. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.","2013","01","Costanza Bogani","CB",8,TRUE,4,5,6,5,TRUE,TRUE,FALSE,0,NA,FALSE
